BR112023017461A2 - Compostos, composição farmacêutica, métodos de tratamento de doença cardíaca, de uma doença ou afecção associada à cardiomiopatia hipertrófica, de uma doença ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, de uma doença ou afecção associada à pequena cavidade ventricular esquerda e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, de uma doença ou afecção selecionada a partir de distrofias musculares e doenças de armazenamento de glicogênio, e, método de inibição do sarcômero cardíaco - Google Patents
Compostos, composição farmacêutica, métodos de tratamento de doença cardíaca, de uma doença ou afecção associada à cardiomiopatia hipertrófica, de uma doença ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, de uma doença ou afecção associada à pequena cavidade ventricular esquerda e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, de uma doença ou afecção selecionada a partir de distrofias musculares e doenças de armazenamento de glicogênio, e, método de inibição do sarcômero cardíacoInfo
- Publication number
- BR112023017461A2 BR112023017461A2 BR112023017461A BR112023017461A BR112023017461A2 BR 112023017461 A2 BR112023017461 A2 BR 112023017461A2 BR 112023017461 A BR112023017461 A BR 112023017461A BR 112023017461 A BR112023017461 A BR 112023017461A BR 112023017461 A2 BR112023017461 A2 BR 112023017461A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- condition
- left ventricular
- cavity
- cardiac
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 8
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000002861 ventricular Effects 0.000 title abstract 4
- 230000000747 cardiac effect Effects 0.000 title abstract 2
- 230000009787 cardiac fibrosis Effects 0.000 title abstract 2
- 230000008602 contraction Effects 0.000 title abstract 2
- 208000007345 glycogen storage disease Diseases 0.000 title abstract 2
- 208000019622 heart disease Diseases 0.000 title abstract 2
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 210000005240 left ventricle Anatomy 0.000 title abstract 2
- 201000006938 muscular dystrophy Diseases 0.000 title abstract 2
- 208000031225 myocardial ischemia Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 210000002235 sarcomere Anatomy 0.000 title abstract 2
- 230000008719 thickening Effects 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156853P | 2021-03-04 | 2021-03-04 | |
| PCT/US2022/018725 WO2022187501A1 (en) | 2021-03-04 | 2022-03-03 | Cardiac sarcomere inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023017461A2 true BR112023017461A2 (pt) | 2023-09-26 |
Family
ID=80937093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023017461A BR112023017461A2 (pt) | 2021-03-04 | 2022-03-03 | Compostos, composição farmacêutica, métodos de tratamento de doença cardíaca, de uma doença ou afecção associada à cardiomiopatia hipertrófica, de uma doença ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, de uma doença ou afecção associada à pequena cavidade ventricular esquerda e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, de uma doença ou afecção selecionada a partir de distrofias musculares e doenças de armazenamento de glicogênio, e, método de inibição do sarcômero cardíaco |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11919909B2 (https=) |
| EP (1) | EP4301760A1 (https=) |
| JP (1) | JP7850737B2 (https=) |
| KR (1) | KR20240015622A (https=) |
| CN (1) | CN117083275A (https=) |
| AR (1) | AR125026A1 (https=) |
| AU (1) | AU2022229390A1 (https=) |
| BR (1) | BR112023017461A2 (https=) |
| CA (1) | CA3209557A1 (https=) |
| CL (2) | CL2023002616A1 (https=) |
| IL (1) | IL305628A (https=) |
| MX (1) | MX2023010125A (https=) |
| TW (1) | TW202302594A (https=) |
| WO (1) | WO2022187501A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020014428A2 (pt) | 2018-01-19 | 2020-12-01 | Cytokinetics, Inc. | composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| EP3814342B1 (en) | 2018-06-26 | 2022-07-27 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| JP7447089B2 (ja) | 2018-08-31 | 2024-03-11 | サイトキネティックス， インコーポレイテッド | 心筋サルコメア阻害剤 |
| MX2023010125A (es) | 2021-03-04 | 2023-09-11 | Cytokinetics Inc | Inhibidores del sarcomero cardiaco. |
| KR20250119513A (ko) * | 2022-09-02 | 2025-08-07 | 싸이토키네틱스, 인코포레이티드 | 5-(3,4-디플루오로벤질)-8-((1r,4r)-4-메틸시클로헥실)-6,9-디옥소-2,5,8-트리아자스피로[3.5]노난-2-카르브알데히드의결정질 형태 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| CN1087725C (zh) | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | 用氘代方法增强药物效果 |
| US5919785A (en) * | 1996-04-03 | 1999-07-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| WO2003059265A2 (en) | 2001-12-21 | 2003-07-24 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| CA2511970C (en) | 2003-01-14 | 2012-06-26 | Cytokinetics, Inc. | Urea derivatives useful in the treatment of heart failure |
| ES2378620T3 (es) | 2003-03-27 | 2012-04-16 | Cytokinetics, Inc. | Sulfonamidas para el tratamiento de insuficiencia cardiaca congestiva, sus composiciones y usos. |
| EP1621540A4 (en) | 2003-04-21 | 2008-07-23 | Ono Pharmaceutical Co | HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN AND USE THEREOF |
| JP5080970B2 (ja) | 2004-06-17 | 2012-11-21 | サイトキネティクス・インコーポレーテッド | 心疾患を治療するための置換尿素誘導体 |
| MX2007006230A (es) | 2004-11-30 | 2007-07-25 | Amgen Inc | Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer. |
| US20060173183A1 (en) | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| MX2007012883A (es) | 2005-04-22 | 2007-12-10 | Wyeth Corp | Derivados de dihidrobenzofurano y usos de los mismos. |
| EP1959962A2 (en) | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| SA08290245B1 (ar) | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
| US20090192168A1 (en) | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
| HRP20140371T1 (hr) | 2009-05-15 | 2014-05-23 | Novartis Ag | Arilpiridini kao inhibitori sinteze aldosterona |
| US8592426B2 (en) | 2011-01-24 | 2013-11-26 | Hoffmann—La Roche Inc. | Aryl-benzocycloalkyl amide derivatives |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| EA024204B1 (ru) | 2012-01-20 | 2016-08-31 | Актелион Фармасьютиклз Лтд. | Производные гетероциклических амидов в качестве антагонистов p2xрецептора |
| SMT202000071T1 (it) | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| US9199945B2 (en) | 2013-06-21 | 2015-12-01 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
| US9663516B2 (en) | 2014-12-18 | 2017-05-30 | MyoKardia, Inc. | Bicyclic-pyrimidinedione compounds |
| CN104539229A (zh) | 2014-12-26 | 2015-04-22 | 金海新源电气江苏有限公司 | 一种太阳能光伏支架 |
| IL295547A (en) | 2015-01-22 | 2022-10-01 | Myokardia Inc | Piperidine-4-methylsulfonyl-modified urea compounds for the treatment of dilated cardiomyopathy (dcm) |
| BR112018012390B1 (pt) | 2015-12-17 | 2023-03-14 | Syngenta Participations Ag | Derivados de oxadiazol microbiocidas |
| EP3390398A1 (en) | 2015-12-18 | 2018-10-24 | Syngenta Participations AG | Microbiocidal oxadiazole derivatives |
| EP3448519A4 (en) | 2016-04-29 | 2020-01-22 | Board Of Regents, The University Of Texas System | SIGMA RECEPTOR BINDING |
| US11066396B2 (en) | 2016-06-23 | 2021-07-20 | Merck Sharp & Dohme Corp. | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors |
| EP3519416B1 (en) | 2016-09-27 | 2021-03-31 | Merck Sharp & Dohme Corp. | Chromane, isochromane and dihydroisobenzofuran derivatives as mglur2-negative allosteric modulators, compositions, and their use |
| WO2018089433A1 (en) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL mTORC INHIBITORS AND USES THEREOF |
| WO2018156883A1 (en) | 2017-02-23 | 2018-08-30 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
| FI3661514T3 (fi) | 2017-08-04 | 2025-12-12 | Myokardia Inc | Mavakamteeni käytettäväksi hypertrofisen kardiomyopatian hoidossa |
| BR112020014428A2 (pt) | 2018-01-19 | 2020-12-01 | Cytokinetics, Inc. | composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| EP3814342B1 (en) | 2018-06-26 | 2022-07-27 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| KR20210054510A (ko) | 2018-08-31 | 2021-05-13 | 제논 파마슈티칼스 인크. | 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도 |
| JP7447089B2 (ja) | 2018-08-31 | 2024-03-11 | サイトキネティックス， インコーポレイテッド | 心筋サルコメア阻害剤 |
| SG11202104218SA (en) | 2018-10-29 | 2021-05-28 | Myokardia Inc | Tetrahydropyran (thp)-substituted bicyclic-pyrimidinedione compounds |
| HRP20240200T1 (hr) | 2019-07-17 | 2024-04-26 | Cytokinetics, Inc. | Oralne formulacije inhibitora kardijskih sarkomera |
| EP3999180B1 (en) | 2019-07-17 | 2024-05-08 | Cytokinetics, Inc. | Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide |
| CN114945372A (zh) | 2019-11-10 | 2022-08-26 | 迈奥卡迪亚公司 | 用肌球蛋白调节剂的治疗方法 |
| CA3190060A1 (en) | 2020-08-28 | 2022-03-03 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
| CN114456163B (zh) | 2020-11-09 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| CN114516843B (zh) | 2020-11-19 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| US20240010639A1 (en) | 2020-11-20 | 2024-01-11 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Triazine dione derivative, preparation method therefor and application thereof in medicine |
| CN114539257B (zh) | 2020-11-24 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用 |
| TW202227402A (zh) | 2020-11-24 | 2022-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 嘧啶二酮類衍生物、其製備方法及其在醫藥上的應用 |
| CN114539229B (zh) | 2020-11-24 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| AR125588A1 (es) | 2021-03-04 | 2023-08-02 | Lilly Co Eli | Compuestos inhibidores de fgfr3 |
| MX2023010125A (es) | 2021-03-04 | 2023-09-11 | Cytokinetics Inc | Inhibidores del sarcomero cardiaco. |
| KR20250119513A (ko) | 2022-09-02 | 2025-08-07 | 싸이토키네틱스, 인코포레이티드 | 5-(3,4-디플루오로벤질)-8-((1r,4r)-4-메틸시클로헥실)-6,9-디옥소-2,5,8-트리아자스피로[3.5]노난-2-카르브알데히드의결정질 형태 |
-
2022
- 2022-03-03 MX MX2023010125A patent/MX2023010125A/es unknown
- 2022-03-03 CN CN202280017911.8A patent/CN117083275A/zh active Pending
- 2022-03-03 BR BR112023017461A patent/BR112023017461A2/pt unknown
- 2022-03-03 AU AU2022229390A patent/AU2022229390A1/en active Pending
- 2022-03-03 EP EP22712689.3A patent/EP4301760A1/en active Pending
- 2022-03-03 IL IL305628A patent/IL305628A/en unknown
- 2022-03-03 US US17/685,778 patent/US11919909B2/en active Active
- 2022-03-03 WO PCT/US2022/018725 patent/WO2022187501A1/en not_active Ceased
- 2022-03-03 CA CA3209557A patent/CA3209557A1/en active Pending
- 2022-03-03 KR KR1020237033052A patent/KR20240015622A/ko active Pending
- 2022-03-03 TW TW111107659A patent/TW202302594A/zh unknown
- 2022-03-03 AR ARP220100486A patent/AR125026A1/es unknown
- 2022-03-03 JP JP2023553393A patent/JP7850737B2/ja active Active
-
2023
- 2023-09-01 CL CL2023002616A patent/CL2023002616A1/es unknown
-
2024
- 2024-01-25 US US18/423,156 patent/US12286437B2/en active Active
- 2024-05-30 CL CL2024001620A patent/CL2024001620A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4301760A1 (en) | 2024-01-10 |
| US11919909B2 (en) | 2024-03-05 |
| CN117083275A (zh) | 2023-11-17 |
| CL2024001620A1 (es) | 2024-11-04 |
| US20220306642A1 (en) | 2022-09-29 |
| AR125026A1 (es) | 2023-05-31 |
| IL305628A (en) | 2023-11-01 |
| US20240309011A1 (en) | 2024-09-19 |
| TW202302594A (zh) | 2023-01-16 |
| MX2023010125A (es) | 2023-09-11 |
| JP7850737B2 (ja) | 2026-04-23 |
| CL2023002616A1 (es) | 2024-02-02 |
| KR20240015622A (ko) | 2024-02-05 |
| CA3209557A1 (en) | 2022-09-09 |
| AU2022229390A1 (en) | 2023-09-21 |
| JP2024508526A (ja) | 2024-02-27 |
| WO2022187501A1 (en) | 2022-09-09 |
| US12286437B2 (en) | 2025-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023017461A2 (pt) | Compostos, composição farmacêutica, métodos de tratamento de doença cardíaca, de uma doença ou afecção associada à cardiomiopatia hipertrófica, de uma doença ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, de uma doença ou afecção associada à pequena cavidade ventricular esquerda e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, de uma doença ou afecção selecionada a partir de distrofias musculares e doenças de armazenamento de glicogênio, e, método de inibição do sarcômero cardíaco | |
| Wit et al. | Triggered activity and atrial fibrillation | |
| JP2012529486A5 (https=) | ||
| US20160030452A1 (en) | Minocycline Derivatives | |
| JOP20210329A1 (ar) | مركبات بيرازول مزدوجة الاستبدال كمثبطات كيتو هيكسو كيناز | |
| JP2018528251A (ja) | 心房細動の予防及び治療のためのドフェチリドとメキシレチンの組合せ | |
| RU2018101439A (ru) | Метаболически устойчивые аналоги cyp-эйкозаноидов для лечения кардиологических заболеваний | |
| SU1470190A3 (ru) | Способ получени 6-/4 @ -ацетил-2-метилимидазол-1-ил/-8-метил-2-/1Н/-карбостирила | |
| US11123328B2 (en) | Dantrolene and analogs thereof for the chronic treatment and prevention of dyssynchronous cardiac dysfunction | |
| IL292696A (en) | Methods for the treatment and/or prevention of severe harmful cardiovascular events with a combination of a bromodomain bet inhibitor and a sodium-dependent glucose transporter 2 inhibitor | |
| NO864514L (no) | Fremgangsmaate for fremstilling av nye thiazoloner. | |
| HU197898B (en) | Process for producing pyridyloxazolone derivative with cardiotonic action | |
| WO2025030135A3 (en) | Methods for treating and ameliorating angina and congestive heart failure | |
| EP2799430B1 (en) | Diphenylmethyl piperazine derivative and pharmaceutical composition using same | |
| Kausel et al. | Bradyarrhythmia as a presenting feature of subclinical hyperthyroidism | |
| RU2185159C2 (ru) | Антиаритмическое средство | |
| Roque et al. | Ventricular tachycardia induced by pacing algorithm designed to avoid atrial fibrillation | |
| Kakavand et al. | Successful management of acute failure of the systemic right ventricle with cardiac resynchronization therapy | |
| Kamakura et al. | Efficacy of quinidine for suppressing Purkinje-related ventricular fibrillation in a patient with hypertrophic cardiomyopathy associated with midventricular obstruction | |
| van Middendorp et al. | Electrophysiological and hemodynamic effects of vernakalant and flecainide during cardiac resynchronization in dyssynchronous canine hearts | |
| CN86107178A (zh) | 用作强心剂的芳酰基噻唑酮的制备方法 | |
| RU2442782C2 (ru) | Производные аминопиперидина как ингибиторы бпхэ (белка-переносчика холестерилового эфира) | |
| Vyas et al. | Coronary sinus as a site for stable temporary atrial pacing to tide over premature ventricular complex–triggered recurrent ventricular fibrillation in a patient with severe left ventricular dysfunction after coronary bypass surgery | |
| RU2345714C2 (ru) | Способ отбора больных хронической сердечной недостаточностью на бивентрикулярную электрокардиостимуляцию | |
| KR102739580B1 (ko) | 후기 나트륨 전류의 증가와 관련된 질환을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |